Managed Healthcare Executive: GLP-1 drugs to drive growth in obesity and diabetes treatment | AMCP Annual 2026 GLP-1 drugs to drive growth in obesity and diabetes treatment | AMCP Annual 2026 The New York Times: New Treatment Lets 3 Transplant Patients Halt Anti-Rejection Drugs The American Journal of Managed Care: New Advances in Diabetes Drugs Are Transforming Treatment of Liver Disease The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments ... Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

Context Explanation

USA TODAY: WhiteSands Alcohol & Drug Rehab Publishes New Website Resource Examining How Long PCP Stays in the Body and Its Impact on Treatment Planning WhiteSands Alcohol & Drug Rehab has published a new educational resource exploring how long phencyclidine, commonly known as PCP, remains in the body and how this timeline influences treatment ...